Covid-19 roundup: AstraZeneca launches new virus R&D division; US buys more of Merck's antiviral pill
AstraZeneca is launching a new division to encompass its vaccine and antibodies businesses.
The subunit will focus on its Covid-19 vaccine and long-acting antibody combination, a company spokesperson told Endpoints News in an email, as AstraZeneca looks to move past its early pandemic stumbles. Iskra Reić, who currently serves as executive VP for Europe and Canada, will lead the division.
“In order to optimise the management of our existing portfolio of vaccines and antibodies for viral respiratory infections, we are creating a dedicated Vaccines and Immune Therapies Unit that brings together R&D, manufacturing, commercial and medical teams,” the spokesperson wrote. “The team will be dedicated to our COVID-19 vaccine, our long-acting antibody combination and our developmental vaccine addressing multiple variants of concern, as well as to our existing portfolio for respiratory viral disease.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters